LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Search

Insulet Corp

Suletud

SektorTervishoid

144.75 1.41

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

141.49

Max

144.77

Põhinäitajad

By Trading Economics

Sissetulek

-11M

91M

Müük

-22M

762M

P/E

Sektori keskmine

36.269

50.102

Aktsiakasum

1.3

Kasumimarginaal

11.96

Töötajad

5,400

EBITDA

-23M

154M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+60.9% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-1.1B

11B

Eelmine avamishind

143.34

Eelmine sulgemishind

144.75

Uudiste sentiment

By Acuity

46%

54%

143 / 344 Pingereas Healthcare

Insulet Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. mai 2026, 19:47 UTC

Tulu

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Insulet Corp Prognoos

Hinnasiht

By TipRanks

60.9% tõus

12 kuu keskmine prognoos

Keskmine 229.53 USD  60.9%

Kõrge 294 USD

Madal 154 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Insulet Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

21 ratings

17

Osta

3

Hoia

1

Müü

Sentiment

By Acuity

143 / 344 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat